Welcome

Session I

Genomic Medicine I: Present and Future of Genomics in Health and Disease

Michael Talkowski
Massachusetts General Hospital, Broad Institute, Meeting Co-Chair

Wendy Chung 
Columbia University, Meeting Co-Chair

Eric Green

National Human Genome Research Institute
“A 2020 strategic vision for improving human health at the forefront of genomics”

Professor Dame Sue Hill

Chief Scientific Officer, National Health Service, (NHS) England
“The power and potential of Genomic Medicine” 

Richard Lifton

Rockefeller University
“From genes and genomes to biology and health”

Cecilia Lindgren

Big Data Institute (BDI), University of Oxford
 “Past, present and future of genomics in health and disease- an ICDA perspective”

Geoffrey Ginsburg

Duke University School of Medicine
“The International 100K+ Cohorts Consortium: Integrating large-scale cohorts to address global scientific challenges”

Session II

Therapeutic Development

Howard McLeod
USF Taneja College of Pharmacy, Session Co-Chair

Penelope Bonnen
Baylor College of Medicine, Session Co-Chair

Mark McCarthy

Genentech
“Deconstructing type 2 diabetes: using genetics and genomics to characterize etiological and clinical heterogeneity”

Alan Shuldiner

Regeneron
“The Regeneron Genetics Center at 6 years of age: What have we learned?”

Frank Bennett

Ionis Pharmaceuticals
“Antisense Oligonucleotide-based therapies for neurological diseases”

Robert Califf

Verily and Google Health
“Precision medicine, personalized medicine, digital medicine – rapidly evolving with the pandemic”

Tim Yu

Boston Children’s Hospital
“Prospects for individualized therapies for orphan diseases”

Session III

Genomics II: New Discoveries, Platforms, and Implementation, Chairs:

Heidi Rehm
Massachusetts General Hospital, Broad Institute, Session Co-Chair

Len Pennacchio
DOE Joint Genome Institute, Lawrence Berkeley National Laboratory, Session Co-Chair

Joseph Gleeson

Rady Genomics Institute, University of California, San Diego
“Genomics and the developing brain”

Emmanouil Dermitzakis

University of Geneva Medical School,

Director Health 2030 Genome Center
“Genetics of 3D genome variation and contribution to disease”

Amit Khera

Massachusetts General Hospital
“Next generation of ‘genome interpretation’ – implications for clinical medicine”

Phil Febbo

illumina
“Whole genome analysis of COVID and us”

Calum MacRae

Brigham and Women’s Hospital
“Acute Medical Genomics: Overcoming the challenges to full clinical implementation”

Sponsor Talks, Demos, and Exhibits

12:30 p.m.-12:40 p.m.

IDT –Ruby Sponsor

DARA AISNER
Colorado Molecular Correlates Laboratory and University of Colorado Department of Pathology
“A Multi-Institutional Collaborative Effort to Facilitate Development and Standardization of Clinical Research Next Generation Sequencing”

12:40 p.m.-12:50 p.m.

Dovetail Genomics, Ruby Sponsor

MARCO BLANCHETTE
Dovetail Genomics
“From Somatic Mutations to Chromatin Topology – Emerging Tools For Epigenetic Biomarker Discovery”

Session IV

Payor Panel and Late Breaking SARS-CoV-2

Stephen Kingsmore, Rady Children’s Institute for Genomic Medicine, Session-Co-Chair and Panel Moderator

Eric Green,  National Human Genome Research Institute,  Session Co-Chair of Late Breaking SARS-CoV-2

Payor Perspectives on Reimbursement of Rapid Genomic Sequencing- Panelists:

John Fox, MD, MHA, Vice President, Associate Chief Medical Officer, Medical Affairs Priority Health

Robert Plass, MD, MMM, Medical Director Policy and Technology Assessment, Blue Shield of California

Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates

Jennifer Malin, MD, PhD, Senior Medical Director, Oncology and Genetics, United Health Group

Late Breaking: SARS-CoV-2

Howard Zucker

Commissioner of Health for New York State

Late Breaking: SARS-CoV-2

Oliver Pybus

Professor of Evolution and Infectious Disease, University of Oxford

Late Breaking: SARS-CoV-2

Jemma Geoghegan

Evolutionary Biologist and Virologist, University of Otago, New Zealand

“COVID-19 in New Zealand: insights from genomics”

Late Breaking: SARS-CoV-2

Kristian Andersen

Director, Infectious Disease Genomics, Scripps Research Translational Institute

Closing Comments